HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use SOMAVERT safely and effectively. See full prescribing information for SOMAVERT. SOMAVERT (pegvisomant) for injection, for subcutaneous use Initial U.S. Approval: 2003 INDICATIONS AND USAGESOMAVERT is a growth hormone receptor antagonist indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-1 (IGF-1) levels. (1) DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHSFor injection: 10 mg, 15 mg, 20 mg, 25 mg or 30 mg lyophilized powder in a single-dose vial for reconstitution supplied with a single-dose vial containing diluent (Sterile Water for Injection, USP) (3) CONTRAINDICATIONSNone (4) WARNINGS AND PRECAUTIONS
ADVERSE REACTIONSMost common reported adverse reactions (>6%) are infection, pain, nausea, diarrhea, abnormal liver tests, flu syndrome, injection site reaction (6) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS
USE IN SPECIFIC POPULATIONSFemales and Males of Reproductive Potential: Advise premenopausal females of the potential for an unintended pregnancy (8.3) See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 7/2023 |
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use SOMAVERT safely and effectively. See full prescribing information for SOMAVERT. SOMAVERT (pegvisomant) for injection, for subcutaneous use Initial U.S. Approval: 2003 INDICATIONS AND USAGESOMAVERT is a growth hormone receptor antagonist indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-1 (IGF-1) levels. (1) DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHSFor injection: 10 mg, 15 mg, 20 mg, 25 mg or 30 mg lyophilized powder in a single-dose vial for reconstitution supplied with a single-dose vial containing diluent (Sterile Water for Injection, USP) (3) CONTRAINDICATIONSNone (4) WARNINGS AND PRECAUTIONS
ADVERSE REACTIONSMost common reported adverse reactions (>6%) are infection, pain, nausea, diarrhea, abnormal liver tests, flu syndrome, injection site reaction (6) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS
USE IN SPECIFIC POPULATIONSFemales and Males of Reproductive Potential: Advise premenopausal females of the potential for an unintended pregnancy (8.3) See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 7/2023 |
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.